tiprankstipranks
Trending News
More News >
Astria Therapeutics (ATXS)
NASDAQ:ATXS
US Market
Advertisement

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Compare
1,075 Followers
See the Price Targets and Ratings of:

ATXS Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Astria
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ATXS Stock 12 Month Forecast

Average Price Target

$29.29
▲(338.47%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Astria Therapeutics in the last 3 months. The average price target is $29.29 with a high forecast of $47.00 and a low forecast of $16.00. The average price target represents a 338.47% change from the last price of $6.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","48":"$48","14.25":"$14.25","25.5":"$25.5","36.75":"$36.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.25,25.5,36.75,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.78,8.027692307692307,11.275384615384615,14.523076923076921,17.77076923076923,21.018461538461537,24.266153846153845,27.513846153846153,30.76153846153846,34.00923076923077,37.25692307692307,40.504615384615384,43.75230769230769,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.78,6.665384615384616,8.55076923076923,10.436153846153847,12.321538461538461,14.206923076923076,16.092307692307692,17.97769230769231,19.86307692307692,21.748461538461537,23.633846153846154,25.51923076923077,27.404615384615383,{"y":29.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.78,5.643076923076923,6.506153846153846,7.36923076923077,8.232307692307693,9.095384615384615,9.958461538461538,10.821538461538461,11.684615384615384,12.547692307692307,13.41076923076923,14.273846153846154,15.136923076923075,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$47.00Average Price Target$29.29Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on ATXS
Jeff JonesOppenheimer
Oppenheimer
$32
Buy
379.04%
Upside
Reiterated
06/16/25
Oppenheimer Keeps Their Buy Rating on Astria Therapeutics (ATXS)
H.C. Wainwright Analyst forecast on ATXS
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$16
Buy
139.52%
Upside
Reiterated
06/13/25
Promising Developments and Consistent Performance Drive Buy Rating for Astria Therapeutics
Citizens JMP Analyst forecast on ATXS
Jonathan WollebenCitizens JMP
Citizens JMP
$25
Buy
274.25%
Upside
Reiterated
05/29/25
Astria Therapeutics (ATXS) Receives a Buy from Citizens JMP
LifeSci Capital Analyst forecast on ATXS
Sam SlutskyLifeSci Capital
LifeSci Capital
$22
Buy
229.34%
Upside
Reiterated
05/29/25
Astria Therapeutics: Favorable Market Position Amid Competitor Safety Concerns
Wedbush
$28
Buy
319.16%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR), Sionna Therapeutics, Inc. (NASDAQ: SION) and Astria Therapeutics (NASDAQ: ATXS)
TD Cowen Analyst forecast on ATXS
Stacy KuTD Cowen
TD Cowen
$35
Buy
423.95%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (NASDAQ: ATXS), Aquestive Therapeutics (NASDAQ: AQST) and Olema Pharmaceuticals (NASDAQ: OLMA)
Cantor Fitzgerald Analyst forecast on ATXS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$47
Buy
603.59%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Astria Therapeutics (NASDAQ: ATXS)
Evercore ISI Analyst forecast on ATXS
Liisa BaykoEvercore ISI
Evercore ISI
$25
Buy
274.25%
Upside
Assigned
01/16/25
Evercore ISI Keeps Their Buy Rating on Astria Therapeutics (ATXS)
Ladenburg Thalmann & Co. Analyst forecast on ATXS
Michael HigginsLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$33
Buy
394.01%
Upside
Reiterated
08/13/24
Buy Rating Affirmed for Astria Therapeutics' Navenibart on Novel Approach and Positive Trial Data
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on ATXS
Jeff JonesOppenheimer
Oppenheimer
$32
Buy
379.04%
Upside
Reiterated
06/16/25
Oppenheimer Keeps Their Buy Rating on Astria Therapeutics (ATXS)
H.C. Wainwright Analyst forecast on ATXS
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$16
Buy
139.52%
Upside
Reiterated
06/13/25
Promising Developments and Consistent Performance Drive Buy Rating for Astria Therapeutics
Citizens JMP Analyst forecast on ATXS
Jonathan WollebenCitizens JMP
Citizens JMP
$25
Buy
274.25%
Upside
Reiterated
05/29/25
Astria Therapeutics (ATXS) Receives a Buy from Citizens JMP
LifeSci Capital Analyst forecast on ATXS
Sam SlutskyLifeSci Capital
LifeSci Capital
$22
Buy
229.34%
Upside
Reiterated
05/29/25
Astria Therapeutics: Favorable Market Position Amid Competitor Safety Concerns
Wedbush
$28
Buy
319.16%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR), Sionna Therapeutics, Inc. (NASDAQ: SION) and Astria Therapeutics (NASDAQ: ATXS)
TD Cowen Analyst forecast on ATXS
Stacy KuTD Cowen
TD Cowen
$35
Buy
423.95%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (NASDAQ: ATXS), Aquestive Therapeutics (NASDAQ: AQST) and Olema Pharmaceuticals (NASDAQ: OLMA)
Cantor Fitzgerald Analyst forecast on ATXS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$47
Buy
603.59%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Astria Therapeutics (NASDAQ: ATXS)
Evercore ISI Analyst forecast on ATXS
Liisa BaykoEvercore ISI
Evercore ISI
$25
Buy
274.25%
Upside
Assigned
01/16/25
Evercore ISI Keeps Their Buy Rating on Astria Therapeutics (ATXS)
Ladenburg Thalmann & Co. Analyst forecast on ATXS
Michael HigginsLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$33
Buy
394.01%
Upside
Reiterated
08/13/24
Buy Rating Affirmed for Astria Therapeutics' Navenibart on Novel Approach and Positive Trial Data
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astria Therapeutics

1 Month
xxx
Success Rate
9/18 ratings generated profit
50%
Average Return
+4.54%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.54% per trade.
3 Months
xxx
Success Rate
7/18 ratings generated profit
39%
Average Return
+16.58%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of +16.58% per trade.
1 Year
Michael HigginsLadenburg Thalmann & Co.
Success Rate
9/18 ratings generated profit
50%
Average Return
+15.34%
reiterated a buy rating 12 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.34% per trade.
2 Years
xxx
Success Rate
8/18 ratings generated profit
44%
Average Return
+6.86%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +6.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATXS Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
14
19
15
19
13
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
19
15
19
13
In the current month, ATXS has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATXS average Analyst price target in the past 3 months is 29.29.
Each month's total comprises the sum of three months' worth of ratings.

ATXS Financial Forecast

ATXS Earnings Forecast

Next quarter’s earnings estimate for ATXS is -$0.59 with a range of -$0.67 to -$0.51. The previous quarter’s EPS was -$0.58. ATXS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year ATXS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ATXS is -$0.59 with a range of -$0.67 to -$0.51. The previous quarter’s EPS was -$0.58. ATXS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year ATXS has Preformed in-line its overall industry.
No data currently available

ATXS Sales Forecast

Next quarter’s sales forecast for ATXS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ATXS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ATXS has Preformed in-line its overall industry.
Next quarter’s sales forecast for ATXS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ATXS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ATXS has Preformed in-line its overall industry.

ATXS Stock Forecast FAQ

What is ATXS’s average 12-month price target, according to analysts?
Based on analyst ratings, Astria Therapeutics’s 12-month average price target is 29.29.
    What is ATXS’s upside potential, based on the analysts’ average price target?
    Astria Therapeutics has 338.47% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ATXS a Buy, Sell or Hold?
          Astria Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Astria Therapeutics’s price target?
            The average price target for Astria Therapeutics is 29.29. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $47.00 ,the lowest forecast is $16.00. The average price target represents 338.47% Increase from the current price of $6.68.
              What do analysts say about Astria Therapeutics?
              Astria Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of ATXS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis